Sam T. Donta, MD; Charles C. Engel, Jr., MD, MPH; Joseph F. Collins, ScD; Joel B. Baseman, PhD; Lisa L. Dever, MD; Thomas Taylor, MD; Kathy D. Boardman, RPh; Lewis E. Kazis, ScD; Suzanne E. Martin; Rebecca A. Horney, BS; Annette L. Wiseman; Douglas S. Kernodle, MD; Raymond P. Smith, MD; Aldona L. Baltch, MD; Christine Handanos, MD; Brian Catto, MD; Luis Montalvo, MD; Michael Everson, PhD; Warren Blackburn, MD; Manisha Thakore, MD; Sheldon T. Brown, MD; Larry Lutwick, MD; Dorothy Norwood, MD; Jack Bernstein, MD; Catherine Bacheller, MD; Bruce Ribner, MD; L. W. Preston Church, MD; Kenneth H. Wilson, MD; Prabhakar Guduru, MD; Robert Cooper, MD; Joseph Lentino, MD; Richard J. Hamill, MD; Arnold B. Gorin, MD; Victor Gordan, MD; David Wagner, MD; Cliff Robinson, MD; Pierre DeJace, MD; Ronald Greenfield, MD; Lisa Beck, MD; Marvin Bittner, MD; H. Ralph Schumacher, MD; Fredric Silverblatt, MD; James Schmitt, MD; Edward Wong, MD; Margaret A.K. Ryan, MD, MPH; Javier Figueroa, MD; Christopher Nice, MD; John R. Feussner, MD, MPH; and the VA Cooperative #475 Group
Researchers have hypothesized that certain Mycoplasma species may cause Gulf War veterans' illnesses (chronic diseases characterized by pain, fatigue, and cognitive symptoms) and that affected patients may benefit from doxycycline treatment. This study found that long-term treatment with doxycycline did not improve outcomes of these illnesses at 1 year.
Ann Intern Med. 2004;141(2):85-94. doi:10.7326/0003-4819-141-2-200407200-00006
Chi-yuan Hsu, MD, MSc; Eric Vittinghoff, PhD; Feng Lin, MS; Michael G. Shlipak, MD, MPH
Growth in incident end-stage renal disease (ESRD) outpaced growth in prevalent chronic renal insufficiency, demonstrating that the ESRD epidemic in the United States is not merely due to more cases of kidney disease. Other potential contributors to ESRD growth are improved survival from nonrenal diseases and more liberal entry criteria for treatment programs.
Ann Intern Med. 2004;141(2):95-101. doi:10.7326/0003-4819-141-2-200407200-00007
Louise Pilote, MD, MPH, PhD; Michal Abrahamowicz, PhD; Eric Rodrigues, MSc; Mark J. Eisenberg, MD, MPH; Elham Rahme, PhD
Survival benefits in the first year after acute myocardial infarction in patients 65 years of age or older seem to differ according to the specific angiotensin-converting enzyme inhibitor prescribed. Ramipril was associated with lower mortality than most other drugs in this class.
Ann Intern Med. 2004;141(2):102-112. doi:10.7326/0003-4819-141-2-200407200-00008
Howard B. Degenholtz, PhD; YongJoo Rhee, MPH, PhD; Robert M. Arnold, MD
Living wills are associated with dying in a patient's residence rather than in a hospital. During advance care planning, physicians should discuss patients' preferences for location of death.
Ann Intern Med. 2004;141(2):113-117. doi:10.7326/0003-4819-141-2-200407200-00009
Christianne L. Roumie, MD; Eric L. Grogan, MD; William Falbe, PharmD; Joseph Awad, MD; Theodore Speroff, PhD; Robert S. Dittus, MD, MPH; Tom A. Elasy, MD, MPH
A multicomponent intervention (patient notification, provider education, electronic alerts in patient chart) seemed to increase the rate of stopping hormone replacement therapy after the release of results from the Women's Health Initiative study in July 2002.
Ann Intern Med. 2004;141(2):118-125. doi:10.7326/0003-4819-141-2-200407200-00010
Yiqing Song, MD; Meir J. Stampfer, MD, DrPH; Simin Liu, MD, ScD
Previous studies on apolipoprotein E (apoE) ϵ4 allele as a risk factor for coronary heart disease have had conflicting results. This meta-analysis found that the apoE ϵ4 allele is strongly implicated as a risk factor for coronary heart disease.
Ann Intern Med. 2004;141(2):137-147. doi:10.7326/0003-4819-141-2-200407200-00013
Stephen E. Possick, MD; Michèle Barry, MD
In the context of a case presentation, the authors review the data on safe air travel after myocardial infarction and common complications of air travel after coronary artery revascularization; provide recommendations on safe air travel after myocardial infarction; discuss the safety of preflight screening and the in-flight environment for patients with pacemakers and implantable automatic defibrillators; and provide recommendations to prevent in-flight deep venous thrombosis.
Ann Intern Med. 2004;141(2):148-154. doi:10.7326/0003-4819-141-2-200407200-00014
Troyen A. Brennan, MD; Thomas H. Lee, MD
The authors describe a patient who believes she is allergic to generic medications and a physician who refuses to prescribe brand-name drugs when generic alternatives are available. They discuss the ethical dilemmas of the patient's physician, who must weigh the interests of a patient who clings to beliefs that the physician thinks are unfounded against the interests of a just rationing program and the broader population it serves.
Ann Intern Med. 2004;141(2):126-130. doi:10.7326/0003-4819-141-2-200407200-00011
Gail J. Povar, MD; Helen Blumen, MD; John Daniel, MD; Suzanne Daub, MSW; Lois Evans, DNSc, RN; Richard P. Holm, MD; Natalie Levkovich; Alice O. McCarter, MSW; James Sabin, MD; Lois Snyder, JD; Daniel Sulmasy, OFM, MD, PhD; Peter Vaughan, PhD; Laurence D. Wellikson, MD; Amy Campbell, JD; and the Medicine as a Profession Managed Care Ethics Working Group*
This statement offers guidance on preserving the patient–physician relationship; patient rights and responsibilities; confidentiality and privacy; resource allocation and stewardship; the obligation of health plans to foster an ethical environment for the delivery of care; and the physician's responsibility to individual patients, the community, and the public health.
Ann Intern Med. 2004;141(2):131-136. doi:10.7326/0003-4819-141-2-200407200-00012
Simon Wessely, MA, BM BCh, MSc, MD, FRCP, FRCPsych
In this issue, Donta and colleagues report that doxycycline treatment has no effect on the health of symptomatic Gulf War veterans and that serologic evidence of Mycoplasma infection was unrelated to health. In the future, we cannot recommend long-term treatment with doxycycline or similar compounds for symptomatic veterans. It would, however, be naive to expect that this negative trial will be the end of the matter.
Ann Intern Med. 2004;141(2):155-156. doi:10.7326/0003-4819-141-2-200407200-00015
Sean Hennessy, PharmD, PhD; Stephen E. Kimmel, MD, MSCE
Pilote and colleagues' study in this issue indicates that in the absence of head-to-head randomized trials that test survival benefits of different angiotensin-converting enzyme inhibitors, the current level of scientific evidence is not sufficient to justify the selection of one proven drug in this class over another.
Ann Intern Med. 2004;141(2):157-158. doi:10.7326/0003-4819-141-2-200407200-00016
Joan M. Teno, MD, MS
In principle, increasing the use of advance directives is important. However, they are not sufficient to address the important concerns of family members of dying patients. We must move from a focus on single interventions, such as the living will, to public policies that use multifaceted interventions to provide competent, coordinated, and compassionate end-of-life care.
Ann Intern Med. 2004;141(2):159-160. doi:10.7326/0003-4819-141-2-200407200-00017
Ann Intern Med. 2004;141(2):161. doi:10.7326/0003-4819-141-2-200407200-00018
Ann Intern Med. 2004;141(2):161. doi:10.7326/0003-4819-141-2-200407200-00019
Ann Intern Med. 2004;141(2):161-162. doi:10.7326/0003-4819-141-2-200407200-00020
Ann Intern Med. 2004;141(2):162. doi:10.7326/0003-4819-141-2-200407200-00021
Ann Intern Med. 2004;141(2):162-163. doi:10.7326/0003-4819-141-2-200407200-00022
Ann Intern Med. 2004;141(2):W-25. doi:10.7326/0003-4819-141-2-200407200-00022-w1
Ann Intern Med. 2004;141(2):163. doi:10.7326/0003-4819-141-2-200407200-00023
Jennifer Fisher Wilson
Ann Intern Med. 2004;141(2):165-168. doi:10.7326/0003-4819-141-2-200407200-00027
Ann Intern Med. 2004;141(2):I-12. doi:10.7326/0003-4819-141-2-200407200-00001
Ann Intern Med. 2004;141(2):I-33. doi:10.7326/0003-4819-141-2-200407200-00002
Ann Intern Med. 2004;141(2):I-34. doi:10.7326/0003-4819-141-2-200407200-00003
Ann Intern Med. 2004;141(2):I-40. doi:10.7326/0003-4819-141-2-200407200-00004
Ann Intern Med. 2004;141(2):I-47. doi:10.7326/0003-4819-141-2-200407200-00005
Marilyn Terranella, MD
Ann Intern Med. 2004;141(2):164. doi:10.7326/0003-4819-141-2-200407200-00025
Kate Scannell, MD
Ann Intern Med. 2004;141(2):164. doi:10.7326/0003-4819-141-2-200407200-00026
Ann Intern Med. 2004;141(2):No Pagination Specified. doi:10.7326/0003-4819-141-2-200407200-00029
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only